Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
First Claim
Patent Images
1. A method for alleviating fatigue arising from an oncological condition, said method comprising the steps of:
- identifying a patient suffering from said fatigue, and administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt.
0 Assignments
0 Petitions
Accused Products
Abstract
In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
-
Citations
56 Claims
-
1. A method for alleviating fatigue arising from an oncological condition, said method comprising the steps of:
-
identifying a patient suffering from said fatigue, and administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (2, 3, 4, 5, 6, 51)
-
-
7. A method for alleviating fatigue arising from the administration of a treatment for an oncological condition, said method comprising the steps of:
-
identifying a patient suffering from said fatigue, and administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (8, 9, 10, 11, 12, 52)
-
-
13. A method for alleviating neurobehavioral slowing arising from an oncological condition, said method comprising the steps of:
-
identifying a patient suffering from said neurobehavioral slowing, and administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (14, 15, 16, 17, 18, 53)
-
-
19. A method for alleviating neurobehavioral slowing arising from the administration of a treatment for an oncological condition, said method comprising the steps of:
-
identifying a patient suffering from said neurobehavioral slowing, and administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 54)
-
-
27. A method for alleviating a cognitive side effect of a treatment for an oncological condition, comprising the steps of:
-
identifing a patient suffering from a cognitive side-effect of a treatment for an oncological condition; and
administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 55)
-
-
39. A method for treating a symptom of menopause comprising the steps of:
-
identifing a patient suffering from a symptom of menopause; and
administering to said patient a unit dosage comprising a compound having the formula or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C4 alkyl, and R2 is hydrogen or C1-C4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage having less than 10% by weight of other stereoisomers of the compound or salt. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 56)
-
Specification